Latest Breaking News On - Kalvista pharmaceuticals - Page 3 : vimarsana.com

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

01.05.2024 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment . Seite 1

Ben palleikoKalvista pharmaceuticals incKalvista pharmaceuticalsChief executive officerKalvista pharmaceuticals chartAlvista pharmaceuticals kursAlvista pharmaceuticals aktie

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 6 8%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 6.8% on Wednesday . The stock traded as high as $12.13 and last traded at $12.12. Approximately 71,232 shares traded hands during trading, a decline of 90% from the average daily volume of 700,371 shares. The stock had previously closed at $11.35. Wall Street Analysts Forecast […]

United statesNew yorkEdwardp feenerVanguard group incKalvista pharmaceuticals incKalvista pharmaceuticalsKalvista pharmaceuticals stockSg americas securitiesNeedham companyMirae asset global investments coChina universal asset management coInstitutional trading of kalvista pharmaceuticalsNews ratings for kalvista pharmaceuticals dailyYork state common retirement fundGet free reportVista pharmaceuticals

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesExperte carsten storkBen palleikoZwei rohstoff chancenBryan bakerJarrod aldomCorporate communicationsKalvista pharmaceuticals incJapanese pharmaceuticalsExchange commissionDrug administrationEuropean medicines agencyDevices agencyVista pharmaceuticalsChief executive officer

KalVista Pharmaceuticals (KALV) Buy Rating Reiterated at Needham & Company LLC

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 191.67% from the stock’s […]

United statesThomas andrew crockettBenjaminl palleikoKalvista pharmaceuticalsSecurities exchange commissionNeedham companyNews ratings for kalvista pharmaceuticals dailyChina universal asset management coYork mellon corpHedge funds weigh in on kalvista pharmaceuticalsKalvista pharmaceuticals stockTower research capitalKalvista pharmaceuticals incGet free reportVista pharmaceuticalsAndrew crockett

Equities Research Analysts Updated EPS Estimates for May 1st (ABX, ACIW, AMD, AMZN, AX, BJRI, CCCS, CECO, CGS, CIVB)

Equities Research Analysts Updated EPS Estimates for May 1st (ABX, ACIW, AMD, AMZN, AX, BJRI, CCCS, CECO, CGS, CIVB)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

William blairPiper sandlerRoth mkmViant technologyKalvista pharmaceuticalsSkyworks solutionsEquities research analystMimedx groupIntelligent solutionsDomino pizza groupCantor fitzgeraldTransmedics groupBarrick gold coTelsey advisory groupTruist financial coCyberark software